Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Findings likely to generate hypotheses about potential new uses of drugs
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The IND application supports the next phase of development of SBO-154
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
Subscribe To Our Newsletter & Stay Updated
